Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. Feagan BG, et al. Among authors: dewit o. Lancet. 2017 Apr 29;389(10080):1699-1709. doi: 10.1016/S0140-6736(17)30570-6. Epub 2017 Apr 12. Lancet. 2017. PMID: 28411872 Free article. Clinical Trial.
The role of aminosalicylates in the treatment of ulcerative colitis.
Van Assche G, Baert F, De Reuck M, De Vos M, De Wit O, Hoang P, Louis E, Mana F, Pelckmans P, Rutgeerts P, Van Gossum A, D'Haens G. Van Assche G, et al. Acta Gastroenterol Belg. 2002 Oct-Dec;65(4):196-9. Acta Gastroenterol Belg. 2002. PMID: 12619425
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Colombel JF, et al. N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492. N Engl J Med. 2010. PMID: 20393175 Free article. Clinical Trial.
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.
De Vos M, Dewit O, D'Haens G, Baert F, Fontaine F, Vermeire S, Franchimont D, Moreels T, Staessen D, Terriere L, Vander Cruyssen B, Louis E; behalf of BIRD. De Vos M, et al. Among authors: dewit o. J Crohns Colitis. 2012 Jun;6(5):557-62. doi: 10.1016/j.crohns.2011.11.002. Epub 2011 Dec 11. J Crohns Colitis. 2012. PMID: 22398050 Free article.
Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol.
Hébuterne X, Lémann M, Bouhnik Y, Dewit O, Dupas JL, Mross M, D'Haens G, Mitchev K, Ernault É, Vermeire S, Brixi-Benmansour H, Moreels TG, Mary JY, Marteau P, Colombel JF. Hébuterne X, et al. Among authors: dewit o. Gut. 2013 Feb;62(2):201-8. doi: 10.1136/gutjnl-2012-302262. Epub 2012 Apr 23. Gut. 2013. PMID: 22525883 Free PMC article. Clinical Trial.
Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
Baert F, Glorieus E, Reenaers C, D'Haens G, Peeters H, Franchimont D, Dewit O, Caenepeel P, Louis E, Van Assche G; BIRD (Belgian IBD Research and Development). Baert F, et al. Among authors: dewit o. J Crohns Colitis. 2013 Mar;7(2):154-60. doi: 10.1016/j.crohns.2012.03.018. Epub 2012 Apr 24. J Crohns Colitis. 2013. PMID: 22537637
118 results